Karyopharm Therapeutics Inc
F:25K0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Karyopharm Therapeutics Inc
F:25K0
|
US |
|
S
|
Sixt SE
XHAM:SIX3
|
DE |
|
C
|
CLARIVATE PLC
F:16A
|
UK |
|
Fuchs Se
F:FPE3
|
DE |
|
Minerals 260 Ltd
ASX:MI6
|
AU |
|
M
|
Minor International PCL
SET:MINT
|
TH |
|
G
|
Graphic Packaging Holding Co
F:4W8
|
US |
|
Unibail-Rodamco-Westfield SE
F:1BR1
|
FR |
Wall St Price Targets
25K0 Price Targets Summary
Karyopharm Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 25K0 is 6.98 EUR with a low forecast of 3.61 EUR and a high forecast of 8.58 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 25K0's stock price target?
Price Target
6.98
EUR
According to Wall Street analysts, the average 1-year price target for 25K0 is 6.98 EUR with a low forecast of 3.61 EUR and a high forecast of 8.58 EUR.
What is the Revenue forecast for Karyopharm Therapeutics Inc?
Projected CAGR
24%
Over the last 13 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 24%.
What is the Gross Profit forecast for Karyopharm Therapeutics Inc?
Projected CAGR
15%
The compound annual growth rate for Gross Profit over the next 3 years is 15%.
